Safety concerns have complicated the development of experimental radiopharmaceutical treatments, with reported effects on patients’ kidneys, liver, and bone marrow.
In an article published by STAT, the debate over how these therapies should be used is examined through the views of Louise Emmett and other specialists.
The field has expanded over the last five years, but those safety issues have created difficulties for drug developers.
At least one company has closed down in recent months, while other organizations have faced problems linked to the treatments.
Emmett is calling on radiopharmaceutical developers to take a less cautious approach.
The article describes her as a leader in the field who works with global drugmakers, including AstraZeneca and Novartis, among others.
Radiopharmaceuticals use radiation-based approaches that experts believe could eliminate cancer cells and extend patients’ lives.
Emmett and like-minded experts argue that patients may be able to receive the treatments more often than current development programs allow.
Their position reflects a concern that pharmaceutical companies are overly fearful of the treatments’ potential power.
Some researchers likewise believe the industry has responded too cautiously because of safety concerns.
The safety problems identified during development involve multiple organs and tissues, rather than a single area of the body.
STAT reports that these effects have contributed to setbacks for companies working on experimental therapies.
The discussion therefore combines an effort to expand dosing with continuing concern about patient safety.
Emmett’s argument is that the field should push further even as developers address the risks that have emerged during its growth.